Detalhe da pesquisa
1.
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol
; 20(3): 131-143, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37807952
2.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
BMC Cancer
; 20(1): 918, 2020 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32988373
3.
Ensuring Diversity and Inclusion in Clinical Development by Leveraging Community Oncology Centers.
J Natl Compr Canc Netw
; 21(8): 889-891, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549916
4.
Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Support Care Cancer
; 26(11): 3773-3780, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29808377
5.
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.
Blood
; 119(19): 4375-82, 2012 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22422823
6.
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
Ann Hematol
; 93(1): 89-98, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24135804
7.
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.
Support Care Cancer
; 22(5): 1223-31, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362907
8.
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Br J Haematol
; 160(3): 321-30, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23150919
9.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Blood Cancer J
; 13(1): 147, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726298
10.
Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
J Manag Care Spec Pharm
; 29(11): 1205-1218, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37776124
11.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Clin Lymphoma Myeloma Leuk
; 20(11): e910-e925, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32912820
12.
Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
Transfusion
; 49(4): 786-96, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19170985
13.
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Am J Hematol
; 84(10): 657-60, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19731393
14.
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
BMC Cancer
; 8: 195, 2008 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18616811
15.
Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
J Manag Care Spec Pharm
; 24(10): 1019-1026, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30247101
16.
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States.
Clin Lymphoma Myeloma Leuk
; 18(2): 152-160, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29395837
17.
Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemotherapy: results from a prospective community-based study.
Clin Lymphoma Myeloma
; 7(6): 413-20, 2007 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-17621407
18.
Treating Multiple Myeloma Patients With Oral Therapies.
Clin Lymphoma Myeloma Leuk
; 17(5): 243-251, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28347676
19.
Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
Oncologist
; 12(4): 484-94, 2007 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-17470691
20.
A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications.
Transfusion
; 43(4): 481-7, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12662281